Seminars in arthritis and rheumatism最新文献_第2页

Characterizing molecular targets in difficult-to-treat rheumatoid arthritis. 确定难以治疗的类风湿性关节炎的分子靶点。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-19 DOI: 10.1016/j.semarthrit.2024.152588

Melanie H Smith, Zilong Bai, Amit Lakhanpal, Daniel Ramirez, Edward DiCarlo, Laura Donlin, Dana Orange, Susan M Goodman

引用次数: 0

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-17 DOI: 10.1016/j.semarthrit.2024.152599

Michael M. Ward

{"title":"Smoking-related bias of standardized mortality ratios in rheumatoid arthritis: A modeling study","authors":"Michael M. Ward","doi":"10.1016/j.semarthrit.2024.152599","DOIUrl":"10.1016/j.semarthrit.2024.152599","url":null,"abstract":"<div><h3>Objective</h3><div>Standardized mortality ratios (SMRs) for rheumatoid arthritis (RA) are age- and sex-matched to the general population, but may be biased because smoking is more common in the RA group. This modeling study used national mortality data on smokers and non-smokers to estimate the effect on SMRs of the higher smoking prevalences typically found in RA.</div></div><div><h3>Methods</h3><div>Data from the United States National Health Interview Surveys 1999–2004 were used to create hypothetical cohorts with an age-sex composition typical of patients with RA (age 30 to 79; 70 % women). The reference cohort had the smoking prevalence of the general population (21.8 % current smokers). Additional cohorts were created that had higher proportions of smokers, approximating the prevalence of smoking commonly present in RA, with smoking relative risks of 1.25, 1.5, 1.75, and 2.0 compared to the reference cohort. SMRs were computed on 2000 replicate samples in which mortality over 10 years and 15 years was compared between the higher-smoking simulated RA cohorts and the reference cohort.</div></div><div><h3>Results</h3><div>The reference cohort had a prevalence of current smoking of 21.8 %. In a hypothetical RA cohort with a higher smoking prevalence, equal to a smoking relative risk of 2.0 compared to the general population, the median SMR for RA was 1.23 at 10 years and 1.17 at 15 years. At a smoking prevalence equivalent to a relative risk of 1.25, the median SMR for RA was 1.07 at 10 years and 1.04 at 15 years. Results were similar for SMRs based on relative risks that compared ever smokers to never smokers. Differences in smoking intensity between the hypothetical RA groups and reference cohorts had small effects on SMRs.</div></div><div><h3>Conclusions</h3><div>SMRs in RA may be inflated by even small increases in the prevalence of smoking relative to the general population. In these cases, an SMR benchmark of 1.0 to represent equal mortality outcomes would be too strict.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152599"},"PeriodicalIF":4.6,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142699531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pathogenesis, diagnostic utility and clinical relevance of cutaneous telangiectasia in systemic sclerosis 系统性硬化症皮肤毛细血管扩张症的发病机制、诊断效用和临床意义

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-17 DOI: 10.1016/j.semarthrit.2024.152593

Aishwarya Anilkumar , Matthew Wells , Robyn T Domsic , Laura K Hummers , Ami A Shah , John D Pauling

引用次数: 0

The overlooked epidemic: Fibromyalgia in the shadows of long COVID. 被忽视的流行病：纤维肌痛在漫长的 COVID 阴影中。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-17 DOI: 10.1016/j.semarthrit.2024.152596

Mariangela Salvato, Andrea Doria, Alessandro Giollo

引用次数: 0

Prediction models for treatment success after an interdisciplinary multimodal pain treatment program 跨学科多模式疼痛治疗计划后治疗成功率的预测模型。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-16 DOI: 10.1016/j.semarthrit.2024.152592

Michel GCAM Mertens , Sander MJ van Kuijk , Laura WME Beckers , Fredrick Zmudzki , Bjorn Winkens , Rob JEM Smeets

{"title":"Prediction models for treatment success after an interdisciplinary multimodal pain treatment program","authors":"Michel GCAM Mertens , Sander MJ van Kuijk , Laura WME Beckers , Fredrick Zmudzki , Bjorn Winkens , Rob JEM Smeets","doi":"10.1016/j.semarthrit.2024.152592","DOIUrl":"10.1016/j.semarthrit.2024.152592","url":null,"abstract":"<div><div>Chronic musculoskeletal pain (CMP) poses a widespread health and socioeconomic problem, being the most prevalent chronic pain condition. Interdisciplinary multimodal pain treatment (IMPT) is considered the gold standard, offering cost-effective long-term care. Unfortunately, only a subset of patients experiences clinically relevant improvements in pain, fatigue, and disability post-IMPT. Establishing a prediction model encompassing various outcome measures could enhance rehabilitation and personalized healthcare. Thus, the aim was to develop and validate a prediction model for IMPT success in patients with CMP. A prospective cohort study within routine care was performed, including patients with CMP undergoing a 10-week IMPT. Success across four outcome measures was determined: patients' recovery perspective, quality of life (physical and mental), and disability. Sixty-five demographic and candidate predictors (mainly patient reported outcome measures) were examined. Finally, 2309 patients participated, with IMPT success rates ranging from 30% to 57%. Four models incorporating 33 predictors were developed, with treatment control being the sole consistent predictor across all models. Additionally, predictors effects varied in direction in the models. All models demonstrated strong calibration, fair to good discrimination, and were internally validated (optimism-corrected AUC range 0.69–0.80). Our findings show that treatment success can be predicted using standardized patient-reported measures, exhibiting strong discriminatory power. However, predictors vary depending on the outcome, underscoring the importance of selecting the appropriate measure upfront. Clinically, these results suggest potential for patient-centered care and may contribute to the development of a scientifically sound decision tool.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152592"},"PeriodicalIF":4.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1? 免疫检查点抑制剂与类风湿性关节炎：所有道路都通向 PD-1？

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-14 DOI: 10.1016/j.semarthrit.2024.152582

Laura C Cappelli

{"title":"Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1?","authors":"Laura C Cappelli","doi":"10.1016/j.semarthrit.2024.152582","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152582","url":null,"abstract":"<p><p>Immune checkpoint molecules like PD-1 and its ligand PD-L1 and CTLA-4 are important regulators of the immune system. Medications blocking these pathways, immune checkpoint inhibitors, have been used to treat a variety of malignancies, while drugs agonizing these pathways, like abatacept, have been used in treating autoimmune diseases. Modulation of the PD-1/PD-L1 axis has become important for rheumatologists to understand in several different clinical scenarios. Currently, PD-1 agonists are being developed for treatment of rheumatoid arthritis (RA). In addition to patients with RA being potentially treated with PD-1 agonists, patients with rheumatoid arthritis may be treated with anti-PD-1/PD-L1 immune checkpoint inhibitors if they develop cancer. Finally, patients treated with immune checkpoint inhibitors may develop de novo inflammatory arthritis and be referred to rheumatology for management. In all three scenarios, there remain many unanswered clinical and translational questions. The parallel development of therapeutics antagonizing and agonizing the PD-1/PD-L1 pathway presents a unique chance for discovery in inflammatory arthritis.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152582"},"PeriodicalIF":4.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatoid arthritis prevention: We need to identify new targets for "NextGen" therapeutic trials. 类风湿性关节炎的预防：我们需要为 "下一代 "治疗试验确定新的目标。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-12 DOI: 10.1016/j.semarthrit.2024.152577

V Michael Holers

引用次数: 0

Defining immune cell phenotypes that distinguish treatment responders and non-responders in RA. 确定区分 RA 治疗应答者和非应答者的免疫细胞表型。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-12 DOI: 10.1016/j.semarthrit.2024.152581

Kathryne E Marks, Alice Horisberger, Daniel H Solomon, Deepak A Rao

引用次数: 0

Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management. 类风湿性关节炎相关间质性肺病：推进识别和管理。

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-10 DOI: 10.1016/j.semarthrit.2024.152578

Bryant R England

{"title":"Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management.","authors":"Bryant R England","doi":"10.1016/j.semarthrit.2024.152578","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2024.152578","url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) that causes substantial morbidity and mortality. Effective, evidence-based strategies to screen for, and manage, RA-ILD are lacking.</p><p><strong>Objectives: </strong>Highlight recent research advances in, and further opportunities to improve, the identification and management of RA-ILD.</p><p><strong>Findings: </strong>The goals of RA-ILD screening are early disease detection while avoiding unnecessary testing. Such an approach requires the ability to accurate risk stratify RA patients. With only a few recognized clinical risk factors for RA-ILD, a growing body of evidence on peripheral biomarkers for RA-ILD appears well suited to support a precision medicine approach. There is a paucity of evidence to guide management after RA-ILD diagnosis. While initial trials of antifibrotics have been conducted in RA-ILD and show the potential to slow the rate of pulmonary function decline, there have been no randomized trials of immunomodulatory therapies in RA-ILD. Supporting such trials, and addressing the barriers to conducting them, is a high priority.</p><p><strong>Conclusion: </strong>Robust characterization of peripheral biomarkers in large, RA populations is essential to inform a precision medicine approach to RA-ILD identification. Randomized trials of treatments and treatment strategies that consider the systemic nature of RA-ILD are necessary to inform evidence-based RA-ILD treatment.</p>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152578"},"PeriodicalIF":4.6,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis? 我们能否通过调节肠道微生物组来提高类风湿关节炎的 DMARD 疗效？

IF 4.6 2区医学

Seminars in arthritis and rheumatism Pub Date : 2024-11-10 DOI: 10.1016/j.semarthrit.2024.152583

Rebecca B Blank, Renuka R Nayak, Jose U Scher

引用次数: 0